



Article

# B-Vitamin Intake and Biomarker Status in Relation to Cognitive Decline in Healthy Older Adults in a 4-Year Follow-Up Study

Catherine F. Hughes <sup>1,\*</sup>, Mary Ward <sup>1</sup>, Fergal Tracey <sup>2</sup>, Leane Hoey <sup>1</sup>, Anne M. Molloy <sup>3</sup>, Kristina Pentieva <sup>1</sup> and Helene McNulty <sup>1</sup>

<sup>1</sup> Northern Ireland Centre for Food and Health, Ulster University, Cromore Road, Coleraine BT52 1SA, Northern Ireland, UK; mw.ward@ulster.ac.uk (M.W.); l.hoey@ulster.ac.uk (L.H.); k.pentieva@ulster.ac.uk (K.P.); h.mcnulty@ulster.ac.uk (H.M.)

<sup>2</sup> Causeway Hospital, Northern Health and Social Care Trust, Coleraine BT52 1HS, Northern Ireland, UK; Fergal.Tracey@northerntrust.hscni.net

<sup>3</sup> School of Medicine, Trinity College Dublin, Dublin <sup>Postal code</sup>, Ireland; AMOLLOY@tcd.ie

\* Correspondence: c.hughes@ulster.ac.uk; Tel.: +44-28-7012-4583

Received: 21 November 2016; Accepted: 4 January 2017; Published: date

**Abstract:** Advancing age can be associated with an increase in cognitive dysfunction, a spectrum of disability that ranges in severity from mild cognitive impairment to dementia. Folate and the other B-vitamins involved in one-carbon metabolism are associated with cognition in ageing but the evidence is not entirely clear. The hypothesis addressed in this study was that lower dietary intake or biomarker status of folate and/or the metabolically related B-vitamins would be associated with a greater than expected rate of cognitive decline over a 4-year follow-up period in healthy older adults. Participants (aged 60–88 years;  $n = 155$ ) who had been previously screened for cognitive function were reassessed four years after initial investigation using the Mini-Mental State Examination (MMSE). At the 4-year follow-up assessment when participants were aged  $73.4 \pm 7.1$  years, mean cognitive MMSE scores had declined from  $29.1 \pm 1.3$  at baseline to  $27.5 \pm 2.4$  ( $p < 0.001$ ), but some 27% of participants showed a greater than expected rate of cognitive decline (i.e., decrease in MMSE  $> 0.56$  points per year). Lower vitamin B6 status, as measured using pyridoxal-5-phosphate (PLP;  $<43$  nmol/L) was associated with a 3.5 times higher risk of accelerated cognitive decline, after adjustment for age and baseline MMSE score (OR, 3.48; 95% CI, 1.58 to 7.63;  $p < 0.05$ ). Correspondingly, lower dietary intake (0.9–1.4 mg/day) of vitamin B6 was also associated with a greater rate of cognitive decline (OR, 4.22; 95% CI, 1.28–13.90;  $p < 0.05$ ). No significant relationships of dietary intake or biomarker status with cognitive decline were observed for the other B-vitamins. In conclusion, lower dietary and biomarker status of vitamin B6 at baseline predicted a greater than expected rate of cognitive decline over a 4-year period in healthy older adults. Vitamin B6 may be an important protective factor in helping maintain cognitive health in ageing.

**Keywords:** one-carbon metabolism; B-vitamin biomarkers; dietary intakes; vitamin B6; pyridoxal-5-phosphate (PLP); cognition; ageing

## 1. Introduction

Advancing age can be associated with an increase in cognitive dysfunction, a spectrum of disability that ranges in severity from normal age-related changes through mild cognitive impairment (MCI) to dementia; with the latter defined as a progressive decline in memory, thinking, language and judgment that is sufficient to impair activities of daily living [1]. An estimated 50% of those diagnosed with MCI will go on to develop dementia within 5 years of diagnosis [2]. Globally, it is estimated that 48 million people are currently suffering from dementia and the figures are

**Commented [M1]:** Please carefully check the accuracy of names and affiliations. Changes will not be possible after proofreading.

**Commented [HC2]:** I can confirm that all author names and affiliations are correct

**Commented [HC3]:** TCD is based in Republic of Ireland and they do not use a postal code system

predicted to triple by 2050 [3]. Dementia is a leading cause of disability, dependency and decreased quality of life among older people [3] and presents many social, economic and health care challenges that will continue to increase with an ageing population. Therefore, the identification of strategies to prevent or delay the onset of dementia has become a major global public health priority.

A number of nutritional and lifestyle factors have emerged as potential modifiable risk factors for cognitive decline in ageing [4]. In particular, there is considerable epidemiological evidence to suggest that sub-optimal status of folate, the related B-vitamins, and/or elevated concentrations of the metabolite homocysteine, contribute to cognitive dysfunction [5–10] and to a greater rate of cognitive decline in ageing [11–14]. Elevated plasma homocysteine and lower folate have been most consistently associated with cognitive dysfunction in ageing [6,8]. There is also evidence to support a role for vitamin B12 [15,16] and to a lesser extent vitamin B6, although the latter has been far less extensively investigated [9,17]. There is also some evidence in the form of randomised controlled trials to show beneficial effects of B-vitamin supplementation on cognition in ageing [18–20]. A number of other trials have failed to detect significant benefits [21–23] with recent meta-analyses concluding that there was no beneficial effect of B-vitamin supplementation on cognition [24,25]. However, a number of these trials may have been too short in duration, included healthy individuals or patients with severe dementia or were conducted in individuals with optimal B-vitamin status and so unlikely to benefit from vitamin supplementation [26]. The strongest evidence to date of a causal relationship between B-vitamins and cognition comes from the Homocysteine and B-vitamin in Cognitive Impairment (VITACOG) study. This study showed that combined B-vitamin supplementation for two years had beneficial effects on cognitive performance in participants with MCI and elevated plasma homocysteine concentrations [20]. More importantly, it also demonstrated that B-vitamin supplementation reduced the rate of brain atrophy by 30% as measured using MRI; [27]. A subsequent report from the VITACOG investigators reported that the atrophy occurred in grey matter areas of the brain which are particularly vulnerable to Alzheimer's disease [28].

The intervention doses administered in VITACOG were well in excess of recommended dietary intakes and therefore whilst the VITACOG papers provide powerful evidence of a role for folate, vitamin B12, and/or vitamin B6 in cognition, the relevance of these results to nutrition, and thus prevention of cognitive dysfunction in ageing is unclear. Furthermore, epidemiological research generally in this area has predominantly focused on plasma homocysteine, folate and vitamin B12; most studies have overlooked vitamin B6 and all have ignored the role of vitamin B2. Consequently, the influence of all the relevant B-vitamins involved in one-carbon metabolism on cognition is not fully understood. Therefore, the aim of this study was to investigate whether lower dietary intake or biomarker status of B-vitamins (folate, vitamin B12, vitamin B6 or riboflavin) at baseline was associated with a greater rate of cognitive decline over a 4-year follow-up period in healthy older adults.

## 2. Materials and Methods

### 2.1. Participant Recruitment and Study Design

Potential participants were identified from our records of a previous cross sectional study funded by the UK Food Standards Agency investigating B-vitamin dietary intakes and biomarker status in the healthy younger and older adults in Northern Ireland as previously described [29]. Healthy participants ( $n = 662$ ; aged  $\geq 18$  years) were recruited to the original study and as part of the protocol, those aged  $\geq 60$  years completed a cognitive function test (Folstein's Mini Mental State Examination MMSE; [30], the purpose of the original assessment was to ensure that the ability of participants to accurately recall food intake was not compromised. The current study involved the re-examination (4 years after initial screening) of those aged  $\geq 60$  years ( $n = 255$ ). The exclusion criteria for the original study were: those with vitamin B12 deficiency (serum vitamin B12  $< 111$  pmol/L); self-reported history of cardiovascular, gastrointestinal, hepatic, renal, or haematological disease; use of medications that interfere with B-vitamin metabolism; taking supplements containing B-vitamins; having visited a country with a mandatory fortification policy for a period  $\geq 2$  weeks in the previous

6 months; plasma creatinine concentrations  $>130 \mu\text{mol/L}$  (generally indicative of renal impairment); and a score of  $<25$  on the MMSE (indicative of cognitive impairment). Ethical approval was granted by the University of Ulster Research Ethics Committee (UUREC; Ref UUREC/07/005) and all participants provided written informed consent.

## 2.2. Cognitive Assessment

Cognitive function was assessed at baseline and at follow-up (between 3.5 to 4 years from initial screening for each participant) using the MMSE [30], one of the most widely used cognitive screening tools in a clinical setting. It is a global test of cognitive function and assesses the domains of orientation, registration, attention and concentration, recall and language. Overall the maximum score achievable is 30, with a score  $<25$  indicating a possibility of cognitive impairment and a score  $<20$  dementia [30].

## 2.3. Dietary and Lifestyle Assessment

Dietary intake was assessed using a 4-day food diary (for 4 consecutive days, including Saturday and Sunday, to account for the known variation in day-to-day intake) in combination with a food frequency questionnaire. This combined dietary method as described previously has been validated at this centre for the assessment of the four relevant B-vitamins against each of their blood biomarkers [29]. The food frequency questionnaire requested participants to state the frequency of consumption for food groups or specific branded products fortified with B-vitamins (e.g., ready-to-eat breakfast cereals, bars, breads and margarines). Participants provided details on brand names of the products consumed so that the fortification profile of any new foods could be established. By combining the 2 dietary collection methods, we were able to estimate dietary intakes of the relevant B-vitamins from both natural food sources and from fortified foods. Each participant received oral and written instructions on how to complete the food diary and food-frequency questionnaire. Any queries or discrepancies between the 2 dietary records were discussed with the participant and were clarified within 1 week of collection to enhance the accuracy of information on usual food intakes. Food portion sizes were estimated by the participant by using household measures and were later quantified by using published food portion size data [31]. The food-composition database WEIGHED INTAKE SOFTWARE PACKAGE (WISP, version 3; Tinuviel Software, Anglesey, UK) was used to calculate mean daily energy and B vitamin intakes. This database has been customised at our centre to enable natural food folate to be distinguished from folic acid added to foods by manufacturers, and this allows the estimation of dietary folate equivalents (DFE; [29]).

A health and lifestyle questionnaire was used to obtain information on medical history including depression, smoking, use of alcohol and medication, and educational attainment. Height (m) and weight (kg) were measured at baseline and body mass index ( $\text{kg/m}^2$ ) was calculated.

## 2.4. Laboratory Analysis

All participants provided a fasting 30 mL blood sample at baseline. Sample preparation and fractionation were performed within 4 h of blood collection, and blood aliquots were stored at  $-80 \text{ }^\circ\text{C}$  until batch analysis. Plasma homocysteine was measured by fluorescence polarization immunoassay using the Abbot Imx analyser [32]. Red blood cell folate was measured by microbiological assay using *Lactobacillus casei* [33]. Vitamin B12 status was determined using a number of biomarkers; the direct measures were serum total vitamin B12 by microbiological assay using *Lactobacillus leichmanni* [34] and serum holoTC (the metabolically active fraction of vitamin B12) by microparticle enzyme immunoassay (AxSym Active-B12; Axis-Shield, City, Germany); the functional biomarker serum methylmalonic acid (MMA) by gas chromatography mass spectrometry using methylchloroformate derivatization at University of Bergen, Norway. Plasma vitamin B6 (PLP) was measured by reversed phase, high performance liquid chromatography with fluorescence detection [35]. Riboflavin status was assessed using the erythrocyte glutathione reductase activation (EGRAC) where the ratio of FAD stimulated to unstimulated enzyme activity is calculated; higher EGRAC values indicate lower

riboflavin status, and sub-optimal riboflavin status is generally recognised as a coefficient  $\geq 1.3$  [36]. The methylenetetrahydrofolate reductase (MTHFR) 677C→T polymorphism was identified by polymerase chain reaction amplification followed by *HinfI* restriction digestion [37]. Plasma creatinine was measured using a standard spectrophotometric assay with use of a chemistry analyzer (Hitachi; Roche Diagnostics Corporation, Indianapolis, IN, USA). Additionally, pepsinogen I and pepsinogen II were measured as markers of gastric atrophy by enzyme-linked immunosorbent assay (Biohit, Helsinki, Finland); a ratio of pepsinogen I:II  $< 3$  is indicative of atrophic gastritis. All samples were analysed blind and duplicated. Quality controls were provided by repeated analysis of pooled samples.

### 2.5. Statistical Analysis

All statistical analysis was performed using SPSS software (version 22; SPSS UK Ltd., Chertsey, UK). Prior to analysis, tests for normality were conducted and data were log transformed where appropriate. Differences at baseline and follow-up were assessed using a paired t-test for continuous data and chi-squared test for categorical data. Correlations between dietary intakes and corresponding blood biomarkers were calculated using Pearson's correlation coefficient ( $r$ ). Annual cognitive decline was calculated  $(\text{baseline MMSE} - \text{follow-up MMSE}) / (\text{duration of follow-up})$  on an individual basis for each participant, accelerated cognitive decline was defined as a decrease in MMSE  $> 0.56$  points per year [38]. Binary logistic regression analysis was used to assess health and lifestyle predictors of cognitive decline. The impact of B-vitamin dietary intake and blood biomarker status as predictors of cognitive decline was assessed using binary logistic regression after controlling for significant predictors of cognitive decline (age and baseline MMSE).


### 3. Results

Of the 662 healthy volunteers, 255  $\geq 60$  years were identified as potential participants and of these 155 were available to participate in the follow-up assessment (Figure 1). Only those that participated at both timepoints are presented in this paper; those lost to follow-up were older and had significantly lower vitamin B12 status (Appendix A).

The characteristics of participants at initial screening are shown in Table 1. Participants had a mean age of 70 years, were predominantly female, well-educated and had a low rate of depression. The majority of participants were regular consumers of foods fortified with B-vitamins (75%). Dietary intakes compared favourably with current UK dietary recommendations [39] as reflected in good overall B-vitamin biomarker status. As a result of the exclusion criteria, no participant was deficient in vitamin B12, however some 3% were identified as deficient in folate and 11% deficient in vitamin B6. Gastric function was assessed by using pepsinogen I:II ratio, 12% had evidence of atrophic gastritis (pepsinogen I:II ratio  $< 3$ ; data not shown).

Commented [M4]: Minus sign?

Commented [M5]: We changed the symbol into  $\frac{\text{ }}{\text{ }}$ . Please confirm.



**Figure 1.** Study Design and flow of participants through the study. Abbreviations: FSA: Food Standards Agency; FFQ: Food Frequency Questionnaire; MMSE: Mini Mental State Examination; <sup>1</sup> Failed to meet inclusion criteria at follow-up assessment  $n = 26$ ; declined to participate  $n = 43$ ; deceased  $n = 4$ ; non contactable  $n = 21$ ; participation in other research  $n = 6$ .

Commented [SF6]: FFQ?

Commented [HC7R6]: FFQ added to abbreviations

**Table 1.** General characteristics of healthy older adults at initial investigation ( $n = 155$ ).

	Participants	Reference Range
Age (years)	69.5 (7.3)	
Male $n$ (%)	60 (39)	
BMI (kg/m <sup>2</sup> )	27.5 (4.2)	20–25
Smokers $n$ (%)	6 (4)	
3rd Level Education $n$ (%)	48 (31)	
Depression $n$ (%) *	11 (7)	
Cognitive Function (MMSE)	29.1 (1.3)	≤25
<b>B-Vitamin Dietary Intakes †</b>		
Energy (MJ/day)	7.621 (1.789)	9.71 (M); 7.96 (F)
Total Folate (µg/day)	303 (141)	200
Vitamin B12 (µg/day)	4.0 (2.4)	1.5
Vitamin B6 (mg/day)	2.3 (0.7)	1.4 (M); 1.2 (F)
Riboflavin (mg/day)	1.6 (0.4)	1.3 (M); 1.1 (F)
Fortified Food Consumer $n$ (%) ‡	116 (75)	
<b>B-Vitamin Biomarker Status §</b>		
Red Blood Cell Folate (nmol/L)	954 (410)	340–2270
<del>Vitamin B12</del>		
Serum total B12 (pmol/L)	282 (106)	111–740
Serum HoloTC (pmol/L)	50.8 (24.3)	40–200
Serum MMA (µmol/L)	0.24 (0.19)	≤0.36
Vitamin B6 (Plasma PLP; nmol/L)	58.4 (25.8)	20–121
Riboflavin (EGRAC)	1.33 (0.14)	≤1.3
Plasma total homocysteine (µmol/L)	12.0 (3.7)	<10

Data presented as mean (SD) unless otherwise indicated. \* History of depression was self-reported.

† Reference ranges for dietary intakes based on reference nutrient intake values (RNIs) for 50+ years except for energy where the estimated energy requirements (EARs) for 65–74 years were used [39].


‡ Consumers of fortified foods were defined as those who consumed foods fortified with B-vitamins at least once per week. § Reference ranges based on analytical laboratory where assay was performed.

Abbreviations: BMI, body mass index; MMSE, mini mental state examination; HoloTC, Holotranscobalamin—functional indicator of metabolically active fraction of vitamin B12; MMA, methylmalonic acid—an indicator of vitamin B12 status, a higher MMA status indicates a lower vitamin B12 status; PLP, Pyridoxal-5-phosphate—a measure of vitamin B6 status; EGRAC, Erythrocyte glutathione reductase activation coefficient—a functional indicator of riboflavin status, a higher ratio indicates a lower riboflavin status

The relationship between dietary intakes and corresponding blood biomarker concentrations were examined for each B-vitamin of interest (Figure 2). Dietary intakes for total folate, vitamin B6 and riboflavin were each significantly correlated with the corresponding blood biomarker concentration. Of note, vitamin B12 intake was significantly correlated with serum holoTC but not serum total vitamin B12, the more typically measured biomarker ( $r = 0.134$ ,  $p = 0.104$ ; data not shown).

Commented [HC8]: This change is finr

Commented [M9]: We changed “≠” into “§”. Please confirm there is no difference here.



**Figure 2.** Relationship between dietary intake and biomarker status of B-vitamins at baseline ( $n = 148$ ). Correlations were calculated using Pearson’s correlation coefficients ( $r$ ).  $p < 0.05$  was considered significant. HoloTC, holo-transcobalamin; PLP, Pyridoxal-5-phosphate—a measure of vitamin B6 status; EGRAC: erythrocyte glutathione reductase activation coefficient, a functional indicator of riboflavin status.

**Commented [M10]:** If there are multiple panels, they should be listed as: **(a)** Description of what is contained in the first panel; **(b)** Description of what is contained in the second panel; **(c)** Description of what is contained in the first panel; **(d)** Description of what is contained in the second panel.

The change in cognitive function score, as measured using MMSE is shown in Table 2. Over the 4-year follow-up period, a significant decline in the mean MMSE by almost 2 points was observed; the scores for each component of the MMSE (i.e., orientation, attention, recall, total verbal and language) also declined significantly, with the exception of registration. Whilst all participants had a MMSE score within the normal range at baseline (i.e., according to the inclusion criteria), 12% had a score indicative of mild cognitive impairment (MMSE range 18–24) at the time of follow-up. Overall, the average decrease in MMSE score per year was  $0.42 \pm 0.56$ ; but some participants 42 (27%) had a greater than expected rate of cognitive decline (i.e., decrease in MMSE score  $> 0.56$  points per year; [38].

**Table 2.** Cognitive Characteristics of healthy older adults at initial examination and after 4-year follow-up ( $n = 155$ ).

Any Heading?	Initial Assessment	Follow-Up Assessment	p-Value
Age	69.5 (7.2)	73.4 (7.1)	<0.001
<b>Cognitive Function Score</b>			
MMSE Total Score	29.1 (1.3)	27.5 (2.4)	<0.001
Orientation	9.9 (0.3)	9.8 (0.7)	0.014
Registration	3.0 (0.1)	3.0 (0.1)	0.565
Attention	4.7 (0.7)	4.4 (1.1)	0.004
Recall	2.7 (0.6)	1.8 (1.0)	<0.001
Total Verbal	20.3 (1.1)	19.0 (2.0)	<0.001
Language	8.8 (0.5)	8.5 (0.8)	<0.001
Impaired Cognition $n$ (%) <sup>#</sup>	0 (0)	19 (12)	

Data presented as mean (standard deviation) unless otherwise indicated. <sup>#</sup> Impaired cognition defined as an MMSE score  $< 25$  [30]. Differences between the two timepoints were assessed using a paired *t*-test.  $p \leq 0.05$  considered statistically significant. Abbreviations: MMSE, Mini mental state examination.

The influence of several lifestyle factors, B-vitamin dietary intake and B-vitamin biomarker status, as determinants of rate of cognitive decline are shown in Table 3. Of the general health and lifestyle factors examined only age and baseline MMSE score were predictive of cognitive decline. In addition, after adjustment for age and baseline MMSE score, no associations were observed between disease history (CVD, diabetes and gastrointestinal; data not shown) or medication use with the exception of use of analgesic medication ( $p = 0.035$ ; data not shown). Vitamin B6 was found to be the only B-vitamin that was predictive of cognitive decline. After adjustment for age and baseline MMSE score, individuals with lower vitamin B6 biomarker status (PLP range  $\leq 43.3$  nmol/L;  $p = 0.002$ ) or lower dietary B6 intakes (0.9–1.4 mg/day;  $p = 0.018$ ) were at a 3.5–4 fold greater risk of cognitive decline. None of the other B vitamins or plasma homocysteine concentrations were associated with the risk of cognitive decline in this cohort.

**Table 3.** Lifestyle factors, B-vitamin dietary intake and B-vitamin biomarker status as predictors of cognitive decline in older adults.

Any Heading?	Range	Odds Ratio	95% CI	p-Value
Age		1.11	(1.05–1.16)	<0.001
Female Gender		0.69	(0.34–1.41)	0.310
BMI		1.04	(0.95–1.13)	0.410
Smoking		2.82	(0.55–14.56)	0.216
MTHFR TT genotype		1.82	(0.56–5.93)	0.318
Secondary level education		1.37	(0.62–3.03)	0.434
Depression		0.40	(0.08–2.18)	0.293
<b>B-Vitamin Biomarker Status</b>				
Low folate status (RCF) *	(191–719 nmol/L)	1.81	(0.83–3.91)	0.134
Low vitamin B12 (serum total B12) *	(118–231 pmol/L)	1.14	(0.52–2.49)	0.750

Commented [M11]: Is the bold necessary?

Commented [HC12]: This is a subheading the table to indicate that we are moving from general characteristic to cognitive function parameter

Commented [M13]: Blank?

Commented [M14]: Please confirm

Commented [HC15]: This is just a symbol for the footnote which informs the reader of the criteria used to define deficiency



Low vitamin B6 (PLP) *	(15.4–42.9 nmol/L)	3.49	(1.60–7.62)	0.002
Low riboflavin status (EGRAC) †	≥1.3	1.01	(0.48–2.15)	0.972
High homocysteine	(12.6–25.4 μmol/L)	1.50	(0.58–3.85)	0.402
<b>B-Vitamin Dietary Intake †</b>				
Low Folate intake	(124–166 μg/day)	2.55	(0.78–8.41)	0.123
Low vitamin B12 intake	(1.2–1.8 μg/day)	1.04	(0.29–3.78)	0.949
Low vitamin B6 intake	(0.9–1.4 mg/day)	4.08	(1.24–13.50)	0.021
Low riboflavin intake	0.6–1.0 mg/day)	0.41	(0.13–1.32)	0.136

Logistic regression was performed to determine predictors of cognitive decline (defined as a decrease in MMSE  $\geq$  0.56 points/year). The reference category for the lifestyle variables were as follows; sex, male gender; education, 3rd level; depression, no history; MTHFR 677 genotype, MTHFR 677 CC and CT genotype combined. \* 'Low' B-vitamin status (with the exception of riboflavin) was defined as the bottom tertile of biomarkers; the reference category was the top two tertiles. † Low riboflavin was defined by established cut-off values for EGRAC (low  $\geq$ 1.3), the reference category was EGRAC < 1.3. ‡ Low dietary intakes were identified by the bottom 10% of intake for each nutrient, the reference category was the remaining intake. Abbreviations: BMI, body mass index; MTHFR, methylenetetrahydrofolate; RCF, red cell folate; PLP, Pyridoxal-5-phosphate; EGRAC, Erythrocyte glutathione reductase activation coefficient.

#### 4. Discussion

This study in healthy older adults, initially with normal cognitive performance, indicates that vitamin B6 is an important predictor of cognitive decline in ageing. Lower dietary intake and biomarker status of vitamin B6 were associated with a greater rate of cognitive decline over a subsequent 4 year follow-up period. No significant association of dietary intake or biomarker status with cognitive decline were observed for the other B-vitamins (folate, vitamin B12 and riboflavin). To our knowledge, this is the first longitudinal study to consider the impact of both dietary intake and biomarker status of all four relevant B-vitamins involved in one-carbon metabolism on cognitive health in ageing.

Whilst the influence of vitamin B6 on cognition has not been as fully investigated as folate and vitamin B12 a number of studies have reported observations consistent with the current study. Our results showed that participants with lower status of vitamin B6 (PLP; the measure of active vitamin B6) at baseline were 3.5 times more likely to have a greater rate of cognitive decline over a 4 year follow-up period. Furthermore, the association between vitamin B6 and cognitive decline was not confined to those with clinical deficiency, lower status included individuals in both the deficient (PLP < 30 nmol/L) and sufficient range (PLP 30–43 nmol/L) which would suggest that optimal vitamin B6 may be important for cognitive health in ageing. Consistent with the biomarker data, those with lower dietary intakes of vitamin B6 at baseline were 4 times more likely to have a greater rate of cognitive decline over the 4 year time period. Our results are in good agreement with findings from other studies, low vitamin B6 status (PLP < 46 nmol/L) and corresponding dietary intakes were previously associated with cognitive decline over a 3 year period in the Veteran Affairs Normative Ageing Study [40]. There is also evidence from several cross sectional studies to support an association between low vitamin B6 and cognitive dysfunction [9,17,41,42] and Alzheimer's disease [43,44]. Furthermore, vitamin B6 status was associated with cognitive performance in high functioning older adults at baseline, though not with cognitive decline over the 7 years follow-up period in the MacArthur study of Successful Ageing [8]. Certain other studies have failed to detect any significant association between vitamin B6 and cognitive function, however, these studies have relied on dietary intake measures alone with no corresponding measurement of blood biomarker status [45–47]. Few RCTs have investigated the independent effect of vitamin B6 on cognitive function and only one very early study reported beneficial effects of vitamin B6 supplementation on memory [19]. Subsequent RCTs have investigated the effect of vitamin B6 in combination with folate and vitamin B12, with some studies reporting beneficial effects on cognitive function however the independent effect of vitamin B6 cannot be determined [18,20].

Whilst elevated plasma homocysteine, low folate and, to a lesser extent, vitamin B12 status have been frequently associated with cognitive decline [11–15,48] there was no evidence of a significant associations for these biomarkers in the current study. A number of other studies have reported similar findings [49–52]. The findings in the current study may be explained to some degree by the fact that vitamin B6 seemed to be the limiting nutrient within the cohort. There was a greater incidence of deficiency of vitamin B6 (11% clinical deficiency) compared with folate (3%) or vitamin B12 (0%). Also, the lack of a significant association between cognitive decline and plasma homocysteine concentration is almost certainly a reflection of the low prevalence of folate deficiency. Furthermore, the concept that the association between B-vitamin status and cognition is determined by the limiting nutrient within that population group is further supported by evidence from published RCTs. One trial of healthy older adults in New Zealand reported no benefit of combined B-vitamin supplementation on cognitive function [21], whereas another similar study from the Netherlands showed that supplementation with folic acid significantly improved cognitive performance [18]. A notable difference between these two studies was that baseline folate status tended to be far lower in the Dutch trial, suggesting that the cognitive benefit related to the correction of sub-optimal B-vitamin status whereas additional B-vitamins to an already optimal population may have no beneficial effect.

The mechanism linking vitamin B6 with cognitive health in this and other studies in ageing is not clear however, it is biologically plausible given the widespread functions of vitamin B6 within the brain and nervous system [53,54]. Vitamin B6 has a crucial role in the synthesis of a variety of neurotransmitters including dopamine and serotonin [55] and can act as a potent antioxidant [56,57]. In addition, higher vitamin B6 intakes have been associated with greater grey matter volume [58] and combined B-vitamin supplementation (including vitamin B6) has been shown to slow brain atrophy, an important feature cognitive dysfunction [27].

The current study has a number of strengths and limitations that merit comment. To our knowledge, this is the first longitudinal study to investigate the association between cognitive decline and all relevant B-vitamins along with their corresponding dietary intakes. The MMSE is the most widely used screening tools for cognitive dysfunction and although it has been criticised for lacking sensitivity, few previous studies have used it to measure cognitive change in a healthy older population. However, a meta-analysis reported a mean decline in MMSE of between 0.16 and 0.56 points per year in cognitively healthy people which compares favourably to the overall rate of decline observed in this study (mean 0.39 points per year) [38]. In addition, the rate of decline observed in this study was identical to that observed in the Rotterdam Study of community dwelling older adults free from cognitive impairment [59]. While the use of the MMSE may be perceived as a limiting factor in the current study, it could be argued that its use would only attenuate the associations observed and that the use of more sensitive tools would have, if anything, detected more subtle differences thus strengthening the results. Another well-recognised limitation of longitudinal studies of this kind is that individuals with the greatest decline in cognitive function are more likely to be lost to follow-up [60]. Indeed, in this study the non-participants were more likely to be older but any non-response bias would ultimately underestimate the associations between baseline B-vitamin status and cognitive decline and this could not have influenced the current findings.

## 5. Conclusions

In conclusion, vitamin B6 may be an important (often overlooked) protective factor in helping maintain cognitive health in ageing, especially in a folate and vitamin B12 replete population. Lower vitamin B6 status (as assessed by both dietary intake and biomarker status) at baseline predicted a greater than expected rate of cognitive decline over a 4-year period in healthy free living older adults. These findings are important because optimising vitamin B6 status in older people, through the use of fortified foods or supplements, may have a positive impact on cognition in ageing. Further research in this area in the form of well-designed randomised controlled trials targeted at populations with sub-optimal status are required in order to confirm a cause and effect relationship between B-vitamin status and cognitive health in ageing.

**Acknowledgments:** This research was part funded by a grant from the United Kingdom Food Standards Agency (Project No. N0505042) and Northern Ireland Department for Employment and Learning (DEL; PhD studentship Catherine F Hughes).

**Author Contributions:** H.M., M.W. and K.P. conceived and designed the experiments; L.H. and C.F.H. performed the experiments; C.F.H. analyzed the data; F.T. provided cognitive assessment training; C.F.H., H.M., M.W. and L.H. wrote the paper. Authorship must be limited to those who have contributed substantially to the work reported.

**Conflicts of Interest:** The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

## Abbreviations

MMSE	Mini mental state examination
HoloTC	Holotranscobalamin—functional indicator of metabolically active fraction of vitamin B12
MMA	methymalonic acid—an indicator of vitamin B12 status, a higher MMA status indicates a lower vitamin B12 status
PLP	Pyridoxal-5-phosphate—a measure of vitamin B6 status
EGRAC	Erythrocyte glutathione reductase activation coefficient—a functional indicator of riboflavin status, a higher ratio indicates a lower riboflavin status

## Appendix A

**Table A1.** A comparison of baseline characteristics between participants and non-participants (i.e., those lost to follow-up).

	Participants (n = 155)	Non-Participants (n = 100)	p-Value
<b>General Characteristics</b>			
Age (years)	69.5 (7.3)	72.2 (8.1)	0.007
Male n (%)	60 (39)	34 (34)	0.530
BMI (kg/m <sup>2</sup> )	27.5 (4.2)	27.3 (3.5)	0.981
Smokers n (%)	6 (4)	5 (5)	
<b>Cognitive Function Score</b>			
MMSE Total Score	29.1 (1.3)	28.7 (1.4)	0.093
Orientation	9.9 (0.3)	9.8 (0.5)	0.140
Registration	3.0 (0.1)	3.0 (0.1)	0.273
Attention	4.7 (0.7)	4.6 (0.9)	0.243
Recall	2.7 (0.6)	2.6 (0.6)	0.825
Total Verbal	20.0 (1.1)	20.0 (1.2)	0.263
Language	8.8 (0.5)	8.6 (0.6)	0.094
<b>B-vitamin Biomarker Status</b>			
Red blood cell folate (nmol/L)	954 (410)	851 (359)	0.080
Vitamin B12			
Serum total vitamin B12 (pmol/L)	282 (106)	257 (127)	0.013
Serum HoloTC (pmol/L)	50.8 (24.3)	47.1 (28.8)	0.381
Serum MMA (µmol/L)	0.24 (0.19)	0.36 (0.56)	0.035
Vitamin B6 (Plasma PLP; nmol/L)	58.4 (25.8)	54.3 (22.9)	0.314
Riboflavin (EGRAC)	1.33 (0.14)	1.34 (0.15)	0.387
Plasma total homocysteine (µmol/L)	12.0 (3.7)	13.1 (4.4)	0.117
<b>Gastric Function</b>			
Pepsinogen I (µg/L)	126.8 (70.8)	135.3 (78.2)	0.515
Pepsinogen Ratio <sup>2</sup>	8.4 (6.7)	8.0 (6.6)	0.713

Values represented as mean (SD). Differences in baseline characteristics between those that participated in the 4-year follow-up and those that did not participate in the follow-up were compared using one-way ANCOVA with adjustment for age for continuous variables (on log transformed data were appropriate). Differences in categorical variables were assessed using Chi-squared analysis.  $p < 0.05$  was significant.

## References

1. McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R., Jr.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the national institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* **2011**, *7*, 263–269.
2. Gauthier, S.; Reisberg, B.; Zaudig, M.; Petersen, R.C.; Ritchie, K.; Broich, K.; Belleville, S.; Brodaty, H.; Bennett, D.; Chertkow, H.; et al. Mild cognitive impairment. *Lancet* **2006**, *367*, 1262–1270.
3. Alzheimer's Disease International. *World Alzheimer Report 2015 the Global Impact of Dementia an Analysis of Prevalence, Incidence, Cost & Trends*; Alzheimer's Disease International (ADI): London, UK, 2015.
4. Morris, M.S. The role of B vitamins in preventing and treating cognitive impairment and decline. *Adv. Nutr.* **2012**, *3*, 801–812.
5. Clarke, R.; Smith, A.; Jobst, K.A.; Refsum, H.; Sutton, L.; Ueland, P.M. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. *Arch. Neurol.* **1998**, *55*, 1449–1455.
6. Doets, E.L.; Ueland, P.M.; Tell, G.S.; Vollset, S.E.; Nygård, O.K.; van't Veer, P.; de Groot, L.C.P.G.M.; Nurk, E.; Refsum, H.; Smith, A.D.; et al. Interactions between plasma concentrations of folate and markers of vitamin B12 status with cognitive performance in elderly people not exposed to folic acid fortification: The hordaland health study. *Br. J. Nutr.* **2014**, *111*, 1085–1095.
7. Ford, A.H.; Flicker, L.; Singh, U.; Hirani, V.; Almeida, O.P. Homocysteine, depression and cognitive function in older adults. *J. Affect. Disord.* **2013**, *151*, 646–651.
8. Kado, D.M.; Karlamangla, A.S.; Huang, M.-H.; Troen, A.; Rowe, J.W.; Selhub, J.; Seeman, T.E. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: Macarthur studies of successful aging. *Am. J. Med.* **2005**, *118*, 161–167.
9. Moorthy, D.; Peter, I.; Scott, T.M.; Parnell, L.D.; Lai, C.-Q.; Crott, J.W.; Ordovás, J.M.; Selhub, J.; Griffith, J.; Rosenberg, I.H.; et al. Status of vitamins B-12 and B-6 but not of folate, homocysteine, and the methylenetetrahydrofolate reductase C677T polymorphism are associated with impaired cognition and depression in adults. *J. Nutr.* **2012**, *142*, 1554–1560.
10. McCaddon, A.; Davies, G.; Hudson, P.; Tandy, S.; Cattell, H. Total serum homocysteine in senile dementia of Alzheimer type. *Int. J. Geriatr. Psychiatry* **1998**, *13*, 235–239.
11. Blasko, I.; Hinterberger, M.; Kemmler, G.; Jungwirth, S.; Krampla, W.; Leitha, T.; Heinz Tragl, K.; Fischer, P. Conversion from mild cognitive impairment to dementia: Influence of folic acid and vitamin B12 use in the vita cohort. *J. Nutr. Health Aging* **2012**, *16*, 687–694.
12. Haan, M.N.; Miller, J.W.; Aiello, A.E.; Whitmer, R.A.; Jagust, W.J.; Mungas, D.M.; Allen, L.H.; Green, R. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: Results from the sacramento area latino study on aging. *Am. J. Clin. Nutr.* **2007**, *85*, 511–517.
13. Hooshmand, B.; Solomon, A.; Kareholt, I.; Rusanen, M.; Hanninen, T.; Leiviska, J.; Winblad, B.; Laatikainen, T.; Soininen, H.; Kivipelto, M. Associations between serum homocysteine, holotranscobalamin, folate and cognition in the elderly: A longitudinal study. *J. Intern. Med.* **2012**, *271*, 204–212.
14. Zylberstein, D.E.; Lissner, L.; Björkelund, C.; Mehlig, K.; Thelle, D.S.; Gustafson, D.; Östling, S.; Waern, M.; Guo, X.; Skoog, I. Midlife homocysteine and late-life dementia in women. A prospective population study. *Neurobiol. Aging* **2011**, *32*, 380–386.
15. Clarke, R.; Birks, J.; Nexo, E.; Ueland, P.M.; Schneede, J.; Scott, J.; Molloy, A.; Evans, J.G. Low vitamin B-12 status and risk of cognitive decline in older adults. *Am. J. Clin. Nutr.* **2007**, *86*, 1384–1391.
16. Morris, M.S.; Selhub, J.; Jacques, P.F. Vitamin B-12 and folate status in relation to decline in scores on the mini-mental state examination in the framingham heart study. *J. Am. Geriatr. Soc.* **2012**, *60*, 1457–1464.
17. Riggs, K.M.; Spiro, A.; Tucker, K.; Rush, D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the normative aging study. *Am. J. Clin. Nutr.* **1996**, *63*, 306–314.
18. Durga, J.; van Boxtel, M.P.J.; Schouten, E.G.; Kok, F.J.; Jolles, J.; Katan, M.B.; Verhoef, P. Effect of 3-year folic acid supplementation on cognitive function in older adults in the facit trial: A randomised, double blind, controlled trial. *Lancet* **2007**, *369*, 208–216.
19. Deijen, J.B.; Beek, E.J.; Orlebeke, J.F.; Berg, H. Vitamin B-6 supplementation in elderly men: Effects on mood, memory, performance and mental effort. *Psychopharmacology* **1992**, *109*, 489–496.
20. De Jager, C.A.; Oulhaj, A.; Jacoby, R.; Refsum, H.; Smith, A.D. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial. *Int. J. Geriatr. Psychiatry* **2012**, *27*, 592–600.

21. McMahon, J.A.; Green, T.J.; Skeaff, C.M.; Knight, R.G.; Mann, J.I.; Williams, S.M. A controlled trial of homocysteine lowering and cognitive performance. *N. Engl. J. Med.* **2006**, *354*, 2764–2772.
22. Ford, A.H.; Flicker, L.; Alfonso, H.; Thomas, J.; Clarnette, R.; Martins, R.; Almeida, O.P. Vitamins B12, B6, and folic acid for cognition in older men. *Neurology* **2010**, *75*, 1540–1547.
23. Van der Zwaluw, N.L.; Dhonukshe-Rutten, R.A.M.; van Wijngaarden, J.P.; Brouwer-Brolsma, E.M.; van de Rest, O.; In 't Veld, P.H.; Enneman, A.W.; van Dijk, S.C.; Ham, A.C.; Swart, K.M.A.; et al. Results of 2-year vitamin B treatment on cognitive performance: Secondary data from an RCT. *Neurology* **2014**, *83*, 2158–2166.
24. Wald, D.S.; Kasturiratne, A.; Simmonds, M. Effect of folic acid, with or without other B vitamins, on cognitive decline: Meta-analysis of randomized trials. *Am. J. Med.* **2010**, *123*, 522–527.
25. Ford, A.H.; Almeida, O.P. Effect of homocysteine lowering treatment on cognitive function: A systematic review and meta-analysis of randomized controlled trials. *J. Alzheimers Dis.* **2012**, *29*, 133–149.
26. McGarel, C.; Pentieva, K.; Strain, J.J.; McNulty, H. Emerging roles for folate and related B-vitamins in brain health across the lifecycle. *Proc. Nutr. Soc.* **2015**, *74*, 46–55.
27. Smith, A.D.; Smith, S.M.; de Jager, C.A.; Whitbread, P.; Johnston, C.; Agacinski, G.; Oulhaj, A.; Bradley, K.M.; Jacoby, R.; Refsum, H. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. *PLoS ONE* **2010**, *5*, e12244.
28. Douaud, G.; Refsum, H.; de Jager, C.A.; Jacoby, R.; Nichols, T.E.; Smith, S.M.; Smith, A.D. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 9523–9528.
29. Hoey, L.; McNulty, H.; Askin, N.; Dunne, A.; Ward, M.; Pentieva, K.; Strain, J.; Molloy, A.M.; Flynn, C.A.; Scott, J.M. Effect of a voluntary food fortification policy on folate, related B vitamin status, and homocysteine in healthy adults. *Am. J. Clin. Nutr.* **2007**, *86*, 1405–1413.
30. Folstein, M.F.; Folstein, S.E.; McHugh, P.R. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. *J. Psychiatr. Res.* **1975**, *12*, 189–198.
31. agency, F.S.
32. Leino, A. Fully automated measurement of total homocysteine in plasma and serum on the Abbott iMx analyzer. *Clin. Chem.* **1999**, *45*, 569–570.
33. Molloy, A.M.; Scott, J.M. Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. In *Methods in Enzymology*; Academic Press: Cambridge, MA, USA, 1997; Volume 281, pp. 43–53.
34. Kelleher, B.P.; Broin, S.D. Microbiological assay for vitamin B12 performed in 96-well microtitre plates. *J. Clin. Pathol.* **1991**, *44*, 592–595.
35. Bates, C.J.; Pentieva, K.D.; Matthews, N.; Macdonald, A. A simple, sensitive and reproducible assay for pyridoxal 5'-phosphate and 4-pyridoxic acid in human plasma. *Clin. Chim. Acta* **1999**, *280*, 101–111.
36. Powers, H.J.; Bates, C.J.; Prentice, A.M.; Lamb, W.H.; Jepson, M.; Bowman, H. The relative effectiveness of iron and iron with riboflavin in correcting a microcytic anaemia in men and children in rural Gambia. *Hum. Nutr. Clin. Nutr.* **1983**, *37*, 413–425.
37. Frosst, P.; Blom, H.J.; Milos, R.; Goyette, P.; Sheppard, C.A.; Matthews, R.G.; Boers, G.J.; den Heijer, M.; Kluijtmans, L.A.; van den Heuvel, L.P.; et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. *Nat. Genet.* **1995**, *10*, 111–113.
38. Park, H.L.; O'Connell, J.E.; Thomson, R.G. A systematic review of cognitive decline in the general elderly population. *Int. J. Geriatr. Psychiatry* **2003**, *18*, 1121–1134.
39. HEALTH, D.O.
40. Tucker, K.L.; Qiao, N.; Scott, T.; Rosenberg, I.; Spiro, A. High homocysteine and low B vitamins predict cognitive decline in aging men: The veterans affairs normative aging study. *Am. J. Clin. Nutr.* **2005**, *82*, 627–635.
41. Bryan, J.; Calvaresi, E.; Hughes, D. Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages. *J. Nutr.* **2002**, *132*, 1345–1356.
42. Kim, H.; Kim, G.; Jang, W.; Kim, S.Y.; Chang, N. Association between intake of B vitamins and cognitive function in elderly Koreans with cognitive impairment. *Nutr. J.* **2014**, *13*, 118.
43. Luchsinger, J.A.; Tang, M.; Miller, J.; Green, R.; Mayeux, R. Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. *Arch. Neurol.* **2007**, *64*, 86–92.
44. Miller, J.W.; Green, R.; Mungas, D.M.; Reed, B.R.; Jagust, W.J. Homocysteine, vitamin B6, and vascular disease in ad patients. *Neurology* **2002**, *58*, 1471–1475.

Commented [M16]: Pls make the reference complete.

Commented [M17]: Pls make the reference complete.

45. Agnew-Blais, J.C.; Wassertheil-Smoller, S.; Kang, J.H.; Hogan, P.E.; Coker, L.H.; Snetselaar, L.G.; Smoller, J.W. Folate, vitamin B6 and vitamin B12 intake and mild cognitive impairment and probable dementia in the women's health initiative memory study. *J. Acad. Nutr. Diet.* **2015**, *115*, 231–241.
46. Nelson, C.; Wengreen, H.J.; Munger, R.G.; Corcoran, C.D.; The Cache County Investigators. Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: The cache county memory, health, and aging study. *J. Nutr. Health Aging* **2009**, *13*, 899–905.
47. Vercambre, M.-N.; Boutron-Ruault, M.-C.; Ritchie, K.; Clavel-Chapelon, F.; Berr, C. Long-term association of food and nutrient intakes with cognitive and functional decline: A 13-year follow-up study of elderly french women. *Br. J. Nutr.* **2009**, *102*, 419–427.
48. Seshadri, S.; Beiser, A.; Selhub, J.; Jacques, P.F.; Rosenberg, I.H.; D'Agostino, R.B.; Wilson, P.W.F.; Wolf, P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N. Engl. J. Med.* **2002**, *346*, 476–483.
49. Eussen, S.J.; de Groot, L.C.; Joosten, L.W.; Bloo, R.J.; Clarke, R.; Ueland, P.M.; Schneede, J.; Blom, H.J.; Hoefnagels, W.H.; van Staveren, W.A. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: A randomized, placebo-controlled trial. *Am. J. Clin. Nutr.* **2006**, *84*, 361–370.
50. Mooijaart, S.P.; Gusssekloo, J.; Frölich, M.; Jolles, J.; Stott, D.J.; Westendorp, R.G.; de Craen, A.J. Homocysteine, vitamin B-12, and folic acid and the risk of cognitive decline in old age: The leiden 85-plus study. *Am. J. Clin. Nutr.* **2005**, *82*, 866–871.
51. Kalmijn, S.; Launer, L.J.; Lindemans, J.; Bots, M.L.; Hofman, A.; Breteler, M.M.B. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: The rotterdam study. *Am. J. Epidemiol.* **1999**, *150*, 283–289.
52. Ravaglia, G.; Forti, P.; Maioli, F.; Vettori, C.; Grossi, G.; Mario Bargossi, A.; Caldarera, M.; Franceschi, C.; Facchini, A.; Mariani, E.; et al. Elevated plasma homocysteine levels in centenarians are not associated with cognitive impairment. *Mech. Ageing Dev.* **2001**, *121*, 251–261.
53. Guilarte, T.R. Vitamin B6 and cognitive development: Recent research findings from human and animal studies. *Nutr. Rev.* **1993**, *51*, 193–198.
54. Wei, I.-L.; Huang, Y.-H.; Wang, G.-S. Vitamin B6 deficiency decreases the glucose utilization in cognitive brain structures of rats. *J. Nutr. Biochem.* **1999**, *10*, 525–531.
55. Karlsson, I. Neurotransmitter changes in aging and dementia. *Nord. J. Psychiatry* **1993**, *47*, 41–44.
56. Kannan, K.; Jain, S.K. Effect of vitamin B6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H<sub>2</sub>O<sub>2</sub>-treated U937 monocytes. *Free Radic. Biol. Med.* **2004**, *36*, 423–428.
57. Shen, J.; Lai, C.-Q.; Mattei, J.; Ordovas, J.M.; Tucker, K.L. Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: The boston puerto rican health study. *Am. J. Clin. Nutr.* **2010**, *91*, 337–342.
58. Erickson, K.I.; Suever, B.L.; Prakash, R.S.; Colcombe, S.J.; McAuley, E.; Kramer, A.F. Greater intake of vitamins B6 and B12 spares gray matter in healthy elderly: A voxel-based morphometry study. *Brain Res.* **2008**, *1199*, 20–26.
59. Zhu, L.; Viitanen, M.; Guo, Z.; Winblad, B.; Fratiglioni, L. Blood pressure reduction, cardiovascular diseases, and cognitive decline in the mini-mental state examination in a community population of normal very old people: A three-year follow-up. *J. Clin. Epidemiol.* **1998**, *51*, 385–391.
60. Lindeboom, J.; Weinstein, H. Neuropsychology of cognitive ageing, minimal cognitive impairment, Alzheimer's disease, and vascular cognitive impairment. *Eur. J. Pharmacol.* **2004**, *490*, 83–86.

